All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Illuccix PSMA-PET Imaging Agent Receives UK Approval in Prostate Cancer

February 13th 2025

The UK Medicines and Healthcare Products Regulatory Agency has approved the kit for the preparation of gallium-68 gozetotide injection.

Talazoparib in Combination With Enzalutamide Improves OS in mCRPC

February 13th 2025

Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.

FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis

February 13th 2025

The designation underscores the potential of the CAR T-cell therapy NXC-201 to serve as a new option in relapsed/refractory AL amyloidosis.

2024 FDA Approvals in Breast, Gynecologic, and Other Solid Tumors Represent Key Steps Forward

February 13th 2025

Experts provide insights on the 2024 FDA approvals in several different fields including solid tumors and more in this list featuring the regulatory decisions.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Obe-Cel Represents a Unique CAR T-Cell Therapy for Patients with Relapsed/Refractory ALL

February 12th 2025

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Open Surgery Approaches and Sequencing Considerations Represent Core Parts of the Shifting Cervical Cancer Field

February 12th 2025

Ritu Salani, MD, MBA, details considerations for cervical cancer treatment as new approvals, research, and modalities affect several settings.

Short-Course Radiation Therapy Effective for Endometrial Cancer Patients

February 12th 2025

Short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

FDA Grants Fast Track Designation to CUSP06 for Platinum-Resistant Ovarian Cancer

February 12th 2025

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

Potential Applications of Cancer Vaccines Continue to Expand in Squamous Cell Carcinoma

February 12th 2025

Omid Hamid, MD, discusses therapies emerging in the squamous cell carcinoma treatment paradigm, including a novel cancer vaccine.

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL

February 12th 2025

The FDA approved brentuximab vedotin plus lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma.

Over a Dozen FDA Approvals in 2024 Changed the Lung Cancer Field

February 12th 2025

This full list of 2024 FDA approvals in lung cancer features insights from experts who sat down with us throughout the year to discuss their significance.

FDA Approves Mirdametinib for NF1-Associated Plexiform Neurofibromas

February 11th 2025

The FDA has approved mirdametinib for patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas.

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

February 11th 2025

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Sotorasib Plus Panitumumab Provides Effective Targeted Therapy Option in KRAS G12C+ mCRC

February 11th 2025

Marwan G. Fakih, MD, discusses the FDA approval of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Fox Chase Cancer Center Researchers Review Guidelines for Therapies Given to Melanoma Patients Before and After Initial Treatment

February 11th 2025

A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.

FDA Accepts BLA Resubmission for Linvoseltamab in R/R Multiple Myeloma

February 11th 2025

A resubmitted biologics license application for linvoseltamab in relapsed/refractory multiple myeloma is under review by the FDA.

Perioperative Pembrolizumab Wins Canadian Approval for Resectable NSCLC

February 11th 2025

Health Canada has approved perioperative pembrolizumab for resectable non–small cell lung cancer.

Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle Cell Lymphoma

February 11th 2025

Zilovertamab vedotin generated responses and was safe in heavily pretreated relapsed/refractory mantle cell lymphoma.